Results 201 to 210 of about 4,957,646 (337)
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald+18 more
wiley +1 more source
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias+12 more
wiley +1 more source
Superior protein titers in half the fermentation time: Promoter and process engineering for the glucose-regulated GTH1 promoter of Pichia pastoris. [PDF]
Prielhofer R+6 more
europepmc +1 more source
Biomedical engineering principles: An introduction to fluid, heat, and mass transport processes (biomedical engineering and instrumentation, volume 2) [PDF]
Peter H. Abbrecht
openalex +1 more source
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley +1 more source
Dip-Coating Process Engineering and Performance Optimization for Three-State Electrochromic Devices. [PDF]
Wu L+7 more
europepmc +1 more source
ENGINEERING DEVELOPMENT OF FLUID-BED FLUORIDE VOLATILITY PROCESSES. PART 11. OFF-GAS ANALYSIS.
D. Ramaswami+4 more
openalex +1 more source
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach+8 more
wiley +1 more source